FAQs

What is the primary business of Resverlogix?

Resverlogix's primary business is the research and development of novel biopharmaceuticals for the treatment of grievous diseases in medical markets with unmet needs. Our primary area of research is in cardiovascular disease, with alternate programs in Alzheimer's disease, autoimmune diseases, diagnostics and device coatings.

What symbol does Resverlogix trade under?

Resverlogix Corp. trades on the Toronto Stock Exchange under the symbol RVX.

Where is the company located?

Resverlogix's head office and laboratory is based in Calgary, Alberta, Canada. Our US office is located in San Francisco, CA.

Cardiovascular Disease FAQ

What is cardiovascular disease?

Cardiovascular disease (CVD) is a broad group of diseases of the heart and blood vessels. The most common cardiovascular diseases arise from the progression of atherosclerosis. The process of atherosclerosis leads to narrowing of the blood vessel lumen and in severe cases leads to complete blockage leading to heart attack and stroke. Over the past few decades it has been established that the risk of CVD can be reduced by enhancing levels of ApoA-I - the key cardioprotective protein of HDL, the “Good” cholesterol.

How is high cholesterol currently treated?

Current treatments for high cholesterol primarily focus on the reduction of low-density lipoprotein (LDL), the "Bad" Cholesterol. While many widely prescribed LDL treatments such as statins effectively slow the buildup of dangerous atherosclerotic plaque, they do little to reduce pre-existing plaque. Statin drugs also have a broad spectrum of potential side effects including severe liver toxicity.

What is high-density lipoprotein?

High-Density Lipoprotein (HDL) is commonly known as "Good" Cholesterol. In a process termed reverse cholesterol transport (RCT), HDL carries cholesterol from the arteries to the liver where it is catabolized and eliminated from the body. The net effect of increasing HDL is an increase in RCT that leads to lower total body cholesterol and a reduced risk of cardiovascular disease. For this reason, HDL is known as "Good" cholesterol.

What is Apolipoprotein A-I (ApoA-I)?

Apolipoprotein A-I (ApoA-I) comprises 70% of the total protein content of HDL. Several studies show a direct relationship between increased ApoA-I and an increase in HDL in the body. Exciting research published in the Journal of the American Medical Association in 2003 showed an injection of a variant of ApoA-I could dramatically reduce pre-existing atherosclerotic plaque.

How do NexVas™ PR small molecules increase ApoA-I?

Resverlogix's molecules increase the transcription of ApoA-I production. This can potentially lead to an innovative method of reducing atherosclerotic plaque.

When will NexVas™ PR small molecules be available to patients?

Like other experimental drugs, NexVas™ PR will not be available to the public until its safety and efficacy has been tested in rigorous clinical trials and approved for use by regulatory bodies such as Health Canada and the U.S. Food & Drug Administration (FDA).

Media

Where can I find news and press releases about Resverlogix?

To view a listing of Resverlogix's press releases, click here.

How do I get photos or videos from you to use in my story?

Please email Corporate Communications and let us know what the photo or video will be used for, any specifications and your deadline.

How do I request an interview with a Resverlogix executive?

Please email Corporate Communications and let us know which Resverlogix executive you would like to interview, the nature of the interview, your contact information and your deadline.

How do I invite a Resverlogix executive to speak at my event?

Please email Corporate Communications and let us know which Resverlogix executive you would like to speak at your event, the nature of the event, your contact information and the date of the event.